Lv1
20 积分 2024-09-08 加入
Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis
11天前
已完结
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
12天前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
13天前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
13天前
已完结
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment
20天前
已完结
The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review
23天前
已完结
Oncolytic virus VG161 in refractory hepatocellular carcinoma
25天前
已完结
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
25天前
已完结
Advancements in second-line treatment research for hepatocellular carcinoma
25天前
已完结
Immunotherapy at all stages of hepatocellular carcinoma
26天前
已完结
皖公网安备34019202002308
